Par Pharma acquires Handa's ANDA for generic Dexilant
This article was originally published in Scrip
Par Pharmaceutical has entered into an exclusive acquisition and licence agreement with Handa Pharmaceuticals to acquire Handa's ANDA for dexlansoprazole capsules delayed release, the generic version of Takeda's proton pump inhibitor Dexilant. However, the ANDA is yet to receive final approval from the US FDA. Dexilant is marketed as a treatment for gastro-oesophageal reflux disease (GORD) and healing of erosive esophagitis, in 30mg and 60mg form.